The Endocannabinoid System (ECS) and receptors are the targeted sites for our nasal and dermal products.
Formulations penetrate through mucosal and dermal barriers to deliver active ingredients.
Nasal inhalation:
- increases bioavailability,
- reduces cough,
- and provides consumption options after dental work.
Dosed nasal sprays can be formulated for local symptom relief or systemic effects.
An overlooked opportunity for better medical acceptance of cannabis with an ability to offer rapid onset, dosing, predicable effects and duration.
Nasal References:
Cannabinoid Control of Olfactory Processes: The
Where Matters.
https://pubmed.ncbi.nlm.nih.gov/32316252/
Endocannabinoid-Mediated Neuromodulation in the Olfactory Bulb: Functional and Therapeutic Significance. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216281/
Cannabinoid Topicals:
- penetrating bases with researched skin permeation,
- 3.5% terpene and essential oil blends,
- real world user feedback,
- and lotions, oils and balms for joints and muscles, and skin.
Dermal formulations offer opportunity for pain and inflammation relief and an entry point for introducing cannabinoid medicine.
Skin References:
Cannabinoid Delivery Systems for Pain and Inflammation Treatment.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222489/.
Our largest organ, the skin has “cutaneous cannabinoid” receptors that are involved in skin homeostasis, barrier formation and regeneration.
Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System
https://pubmed.ncbi.nlm.nih.gov/30845666/.